Hypoplastic Left Heart Syndrome (HLHS) – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030
Hypoplastic left heart syndrome (HLHS) is a complex combination of cardiac malformations that probably results from multiple developmental errors in the early stages of cardiogenesis and that, if left untreated, invariably prove fatal. A variety of chest radiographic findings is seen in patients with HLHS, including an enlarged cardiac silhouette (notably a prominent right atrium), pulmonary venous hypertension, an atrial septal defect, and valvular stenosis or atresia. In HLHS, pulmonary venous blood enters the left atrium, but atrial systole cannot push blood across the atretic or stenotic mitral valve into the hypoplastic left ventricle. Consequently, left atrial blood is shunted across interatrial communication. The interatrial defect can range from a highly restrictive pinhole-sized foramen ovale to a wide, nonrestrictive atrial septal defect. Most commonly, the foramen ovale restricts left-to-right shunting. This restricted flow, coupled with decreased flow through the mitral valve, causes pulmonary venous outflow obstruction, resulting in the typical presentation of a neonate with severe congestive heart failure.
HLHS has a
reported prevalence of 0.2 per 1,000 live births and occurs twice as often in
boys as in girls. Left untreated, HLHS is invariably lethal and is responsible
for 25% of early cardiac deaths in neonates.
The competitive
landscape of Hypoplastic Left Heart Syndrome (HLHS) includes country-specific
approved and pipeline therapies. Any asset/product-specific designation or
review and Accelerated Approval are tracked and supplemented with analyst
commentary.
KOLs insights of Hypoplastic
Left Heart Syndrome (HLHS) across 8 MM market from the center of Excellence/
Public/ Private hospitals participated in the study. Insights around current
treatment landscape, epidemiology, clinical characteristics, future treatment
paradigm, and Unmet needs.
Hypoplastic
Left Heart Syndrome (HLHS) Market
Forecast: Patient Based Forecast Model (MS. Excel Based Automated
Dashboard) which Data Inputs with sourcing, Market Event, and Product Event,
Country specific Forecast Model, Market uptake and patient share uptake,
Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario,
Summary, and Insights.
S. No Asset Company Stage
1 Lomecel-B Longeveron
Inc. Phase 2
2 JRM-001 Japan
Regenerative Medicine Co., Ltd. Phase 3
3 Curosurf Chiesi
Farmaceutici S.p.A. Phase 1
Comments
Post a Comment